Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Recruiting 6Enrolling by invitation 2Completed 2Active not recruiting 2Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Cancer Risk Syndrome 1Breast Neoplasms 1

Interventions

pembrolizumab 374Carboplatin 276Specimen Handling 265Nivolumab 252Magnetic Resonance Spectroscopy 244Cyclophosphamide 240Cisplatin 213Paclitaxel 206Radiotherapy 195Biopsy 171Gemcitabine 155Dexamethasone 148durvalumab 143atezolizumab 126Rituximab 120Doxorubicin 115Bevacizumab 114Lenalidomide 113Ipilimumab 111Radiation 109Docetaxel 103Pemetrexed 102Etoposide 101fludarabine 97venetoclax 95Fluorouracil 92Capecitabine 92Radiosurgery 90Prednisone 89Oxaliplatin 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Genetic Counseling × 1 year × Clear all
NCT04323774 2025-12-12

AYA-RISE

Dana-Farber Cancer Institute

Phase NA Active not recruiting
115 enrolled

Cancer Risk Syndrome

NCT05325151 2025-12-11

Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer

Ohio State University Comprehensive Cancer Center

Phase NA Active not recruiting
874 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡